AZN

Astrazeneca (AZN)

Company name:	Astrazeneca Plc
Company Description:	A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
EPIC:	AZN	Trading Currency:	GBX
Market Sector:	FE10	ISIN:	GB0009895292
Market Segment:	SET1	Share Type:	DE
WWW Address:	http://www.astrazeneca.com/	Description:	ORD SHS $0.25
Industry Sector:	PHARMACEUTICALS & BIOTECHNOLOGY

Price	Price Change [%]	Bid	Ask	Open	High	Low	Volume
8,336.00	-72.0 [-0.86]	8,336.00	8,338.00	8,357.00	8,377.00	8,270.00	453,731
Market Cap. [m]	Shares In Issue [m]	Beta	EPS	DPS	PE Ratio	Yield	52-Wks-Range
109,428.31	1,312.72	-2.06	176.72	204.80	47.17	2.46	10,120.00 - 6,736.00

Astrazeneca Key Figures

Key Figures
(at previous day's close)
Market Cap.	109,428.31	m
Shares In Issue	1,312.72	m
Prev. Close	8,408.00
PE Ratio	47.17
Dividend Yield	2.46	%
EPS - basic	176.72	p
Dividend PS	204.80	p
Dividend Cover	-
Cash Flow PS	267.39	p
Return On Equity (ROE)	20.46	%
Operating Margin	14.71	%
PEG Factor	0.34
EPS Growth Rate	136.89	%
Dividends PS Growth Rate	-	%
Net Debt	31,640.46	m
Gross Gearing	76.56	%
Quick Assets	14,171.98	m
Net Working Capital	2,262.28	m
Intangibles / Fixed Assets	77.22	%
Turnover PS	1,483.04	p
Pre-Tax Profit PS	218.19	p
Retained Profit PS	-20.95	p
Cash PS	436.38	p
Net Cash PS	-695.08	p
Net Tangible Asset Value PS *	-993.78	p
Net Asset Value PS	871.32	p
Spread	2.00 (0.02%)
* Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies.

Astrazeneca Balance Sheet

%1$s Balance Sheet

Share Price Performance

Share Price Performance
Sample Period ^†	High	Low
1 week	8,476.00	8,270.00
4 weeks	8,476.00	7,870.00
12 weeks	8,476.00	7,045.00
1 year	10,120.00	6,736.00

Share Price Chart (5 years)

Astrazeneca Historic Returns

%1$s Historic Returns
Giorni da oggi ^†	Open	Change	%	Open Avg.	Avg. Daily Vol [m]	Total Vol [m]	VWAP
1 week	8,390.00	-54.00	-0.64	8,270.00	2.18		8,386.11
4 weeks	8,100.00	236.00	2.91	7,870.00	2.34		8,179.34
12 weeks	7,398.00	938.00	12.68	7,045.00	2.32		7,767.24
26 weeks	7,364.00	972.00	13.20	6,736.00	2.64		7,486.77
1 year	8,492.00	-156.00	-1.84	6,736.00	2.31		7,841.33
3 years	5,236.00	3,100.00	59.21	5,110.00	2.32		7,070.27
5 years	3,877.00	4,459.00	115.01	3,680.00	2.42		6,108.41
† periods calculated are whole weeks rather than calendar months

Astrazeneca Key Management Ratios

DEEPER ANALYSIS

Astrazeneca Investment Ratios

%1$s Investment Ratios
(Market value analysis) at previous day's close
PQ Ratio	103.62
PE Ratio	47.17
Tobin's Q Ratio	1.71
Tobin's Q Ratio (excl. intangibles)	3.56
Dividend Yield	2.46	%
Market-to-Book Ratio	9.58
Price-to-Pre-Tax Profit PS	38.21
Price-to-Retained Profit PS	-397.90
Price-to-Cash Flow PS	31.18
Price-to-Sales PS	5.62
Price-to-Net Tangible Asset Value PS	-8.40
Price-to-Cash PS	19.10
Net Working Capital PS	172.34
Price Pct to Working Capital PS	48.37	%
Earnings Yield	2.12	%
Average PE	35.20
Years in average	5
PE to PE average	134.01	%

Astrazeneca Financial Ratios

%1$s Financial Ratios
(Leverage Ratios)
Debt Ratio	66.31	%
Debt-to-Equity Ratio	1.97
Debt-to-Equity Ratio (excl. Intgbl)	-1.73
Debt-to-Equity Market Value	0.21
Net Gearing	64.83	%
Net Gearing (excl. Intangibles)	130.02	%
Gross Gearing	76.56	%
Gross Gearing (excl. Intangibles)	153.56	%
Gearing Under 1 Year	30.43	%
Gearing Under 1 Year (excl. Intgbl)	61.04	%
Assets/Equity	4.27
Cash/Equity	50.08
(Liquidity Ratios)
Net Working Capital to Total Assets	4.64	%
Current Ratio	1.15
Quick Ratio (Acid Test)	0.95
Liquidity Ratio	0.39
Cash & Equiv/Current Assets	33.47	%
(Solvency Ratios)
Enterprise Value	126,227.54	m
CFO/Sales	0.18
CFO/Attributable Profit	1.50
CFO/Assets	0.07
CFO/Debt	0.09
Total Debt/Equity Market Value	0.34
Total Debt/Sales	1.92
Total Debt/Pre-Tax Profit	13.05
Total Debt	37,368.94	m
Total Debt/Net Current Assets	16.52	%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth	12.80	%
5 yr Compound Earnings Growth	-	%
10 yr Compound Earnings Growth	-	%
Earn drops > 5% in 10yrs	9

Beta coefficients
Beta (60-Mnth)	Beta (36-Mnth)
-2.0555	-1.6556

Astrazeneca Operating Ratios

%1$s Operating Ratios
(Profitability Ratios)
Return On Capital Employed (ROCE)	8.44	%
Return On Assets (ROA)	3.65	%
Net Profit Margin	12.01	%
Assets Turnover	0.30
Return On Equity (ROE)	20.46	%
Return On Investment (ROI)	5.21	%
Dividend Payout Ratio	114.75	%
Plowback Ratio	-14.75	%
Growth from Plowback Ratio	-2.40	%
Net Income Of Revenues	-1.41	%
(Asset Utilisation Multiples)
Shareholders Equity Turnover	1.35
Fixed Assets Turnover	0.45
Current Assets Turnover	0.94
Net Working Capital Turnover
Inventory Turnover	5.40
(Other Operating Ratios)
Total Assets-to-Sales	3.29
Debtors-to-Sales	54.06	%
Debt Collection Period	197.31	Days

Astrazeneca Dividends

%1$s Dividends
Announcement Date	Type	Curr.	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
16 Feb 2021	Interim	USX	190.00	12/31/2019	12/31/2020	02/25/2021	02/26/2021	03/29/2021	280.00
30 Jul 2020	Interim	USX	90.00	12/31/2019	12/31/2020	08/13/2020	08/14/2020	09/14/2020	-
14 Feb 2020	Interim	USX	190.00	12/31/2018	12/31/2019	02/27/2020	02/28/2020	03/30/2020	280.00
25 Jul 2019	Interim	USX	90.00	12/31/2018	12/31/2019	08/08/2019	08/09/2019	09/09/2019	-
14 Feb 2019	Final	USX	190.00	12/31/2017	12/31/2018	02/28/2019	03/01/2019	03/27/2019	280.00
26 Jul 2018	Interim	USX	90.00	12/31/2017	12/31/2018	08/09/2018	08/10/2018	09/10/2018	-
02 Feb 2018	Final	USX	190.00	12/31/2016	12/31/2017	02/15/2018	02/16/2018	03/19/2018	280.00
27 Jul 2017	Interim	USX	90.00	12/31/2016	12/31/2017	08/10/2017	08/11/2017	09/11/2017	-
02 Feb 2017	Final	USX	190.00	12/31/2015	12/31/2016	02/16/2017	02/17/2017	03/20/2017	280.00
28 Jul 2016	Interim	USX	90.00	12/31/2015	12/31/2016	08/11/2016	08/12/2016	09/12/2016	-
04 Feb 2016	Final	USX	190.00	12/31/2014	12/31/2015	02/18/2016	02/19/2016	03/21/2016	280.00
30 Jul 2015	Interim	USX	90.00	12/31/2014	12/31/2015	08/13/2015	08/14/2015	09/14/2015	-
05 Feb 2015	Final	USX	190.00	12/31/2013	12/31/2014	02/19/2015	02/20/2015	03/23/2015	280.00
31 Jul 2014	Interim	USX	90.00	12/31/2013	12/31/2014	08/13/2014	08/15/2014	09/15/2014	-
06 Feb 2014	Final	USX	190.00	12/31/2012	12/31/2013	02/19/2014	02/21/2014	03/24/2014	280.00
01 Aug 2013	Interim	USX	90.00	12/31/2012	12/31/2013	08/14/2013	08/16/2013	09/16/2013	-
31 Jan 2013	Final	USX	190.00	12/31/2011	12/31/2012	02/13/2013	02/15/2013	03/18/2013	280.00
26 Jul 2012	Interim	USX	90.00	12/31/2011	12/31/2012	08/08/2012	08/10/2012	09/10/2012	-
02 Feb 2012	Final	USX	195.00	12/31/2010	12/31/2011	02/15/2012	02/17/2012	03/19/2012	280.00
28 Jul 2011	Interim	USX	85.00	12/31/2010	12/31/2011	08/03/2011	08/05/2011	09/12/2011	-
27 Jan 2011	Final	USX	185.00	12/31/2009	12/31/2010	02/02/2011	02/04/2011	03/14/2011	255.00
29 Jul 2010	Interim	USX	70.00	12/31/2009	12/31/2010	08/02/2010	08/04/2010	09/13/2010	-
28 Jan 2010	Final	USX	171.00	12/31/2008	12/31/2009	02/03/2010	02/05/2010	03/15/2010	230.00
30 Jul 2009	Interim	USX	59.00	12/30/2008	06/30/2009	08/05/2009	08/07/2009	09/14/2009	-
29 Jan 2009	Final	USX	150.00	12/31/2007	12/31/2008	02/04/2009	02/06/2009	03/16/2009	205.00
31 Jul 2008	Interim	USX	55.00	12/30/2007	06/30/2008	08/08/2008	08/06/2008	09/15/2008	-
31 Jan 2008	Final	USX	135.00	12/31/2006	12/31/2007	02/06/2008	02/08/2008	03/17/2008	187.00
26 Jul 2007	Interim	USX	52.00	06/30/2006	06/30/2007	08/08/2007	08/10/2007	09/17/2007	-
01 Feb 2007	Final	USX	123.00	12/31/2005	12/31/2006	02/07/2007	02/09/2007	03/19/2007	172.00
27 Jul 2006	Interim	USX	49.00	12/30/2005	06/30/2006	08/09/2006	08/11/2006	09/18/2006	-
01 Feb 2006	Final	USX	92.00	12/31/2004	12/31/2005	02/08/2006	02/10/2006	03/20/2006	130.00
29 Jul 2005	Interim	USX	38.00	12/30/2004	06/30/2005	08/10/2005	08/12/2005	09/19/2005	-
27 Jan 2005	Final	USX	64.50	12/31/2003	12/31/2004	02/09/2005	02/11/2005	03/21/2005	94.00
22 Jul 2004	Interim	USX	29.50	12/30/2003	06/30/2004	08/11/2004	08/13/2004	09/20/2004	-
29 Jan 2004	Final	USX	54.00	12/31/2002	12/31/2003	02/18/2004	02/20/2004	04/06/2004	79.50
24 Jul 2003	Interim	USX	25.50	12/30/2002	06/30/2003	08/20/2003	08/22/2003	10/06/2003	-
30 Jan 2003	Final	USX	47.00	12/31/2001	12/31/2002	02/19/2003	02/21/2003	04/07/2003	70.00
25 Jul 2002	Interim	USX	23.00	12/30/2001	06/30/2002	08/21/2002	08/23/2002	10/07/2002	-
31 Jan 2002	Final	USX	47.00	12/31/2000	12/31/2001	02/20/2002	02/22/2002	04/08/2002	70.00
26 Jul 2001	Interim	USX	23.00	12/30/2000	06/30/2001	08/22/2001	08/24/2001	10/05/2001	-
08 Feb 2001	Final	USX	47.00	12/31/1999	12/31/2000	02/21/2001	02/23/2001	04/09/2001	70.00
01 Aug 2000	Interim	USX	23.00	12/30/1999	06/30/2000	09/04/2000	09/08/2000	10/23/2000	-
24 Feb 2000	Final	USX	47.00	12/31/1998	12/31/1999	03/06/2000	03/10/2000	04/17/2000	70.00
03 Aug 1999	Interim	USX	23.00	12/30/1998	06/30/1999	09/06/1999	09/10/1999	10/25/1999	-

Astrazeneca Fundamentals

Profit and Loss Account
	31 Dec 2017 (USD)		31 Dec 2018 (USD)		31 Dec 2019 (USD)		31 Dec 2020 (USD)
turnover	22,465.00	100.00%	22,090.00	100.00%	24,384.00	100.00%	26,617.00	100.00%	m
pre tax profit	2,227.00	9.91%	1,993.00	9.02%	1,548.00	6.35%	3,916.00	14.71%	m
attributable profit	3,001.00	13.36%	2,155.00	9.76%	1,335.00	5.47%	3,196.00	12.01%	m
retained profit	-518.00	-2.31%	-1,329.00	-6.02%	-2,257.00	-9.26%	-376.00	-1.41%	m
eps - basic	237.00		170.00		103.00		244.00
eps - diluted	237.00		170.00		103.00		244.00
dividends per share	280.00		280.00		280.00		280.00

Astrazeneca Balance Sheet

Balance Sheet
	31 Dec 2017 (USD)		31 Dec 2018 (USD)		31 Dec 2019 (USD)		31 Dec 2020 (USD)


	31 Dec 2017 (USD)		31 Dec 2018 (USD)		31 Dec 2019 (USD)		31 Dec 2020 (USD)
ASSETS
fixed assets	7,615.00	12.02%	7,421.00	12.24%	7,688.00	12.53%	8,251.00	12.36%	m
intangibles	38,013.00	60.00%	33,666.00	55.51%	33,148.00	54.01%	33,458.00	50.14%	m
fixed investments	2,798.00	4.42%	2,186.00	3.60%	2,405.00	3.92%	1,620.00	2.43%	m
current assets - other	-	-%	-	-%	70.00	0.11%	-	-%	m
stocks	3,035.00	4.79%	2,890.00	4.76%	3,193.00	5.20%	4,024.00	6.03%	m
debtors	8,569.00	13.53%	9,657.00	15.92%	9,504.00	15.48%	11,544.00	17.30%	m
cash & securities	3,324.00	5.25%	4,831.00	7.97%	5,369.00	8.75%	7,832.00	11.74%	m

TOTAL	63,354.00	100%	60,651.00	100%	61,377.00	100%	66,729.00	100%	m

LIABILITIES
creditors - short	16,383.00	25.86%	16,292.00	26.86%	18,117.00	29.52%	20,307.00	30.43%	m
creditors - long	30,329.00	47.87%	30,315.00	49.98%	28,664.00	46.70%	30,784.00	46.13%	m
creditors - other	-	-%	-	-%	-	-%	-	-%	m
subordinated loans	-	-%	-	-%	-	-%	-	-%	m
insurance funds	-	-%	-	-%	-	-%	-	-%	m

TOTAL	46,712.00	73.73%	46,607.00	76.84%	46,781.00	76.22%	51,091.00	76.56%	m

EQUITY
ord cap, reserves	14,960.00	23.61%	12,468.00	20.56%	13,127.00	21.39%	15,622.00	23.41%	m
prefs, minorities	1,682.00	2.65%	1,576.00	2.60%	1,469.00	2.39%	16.00	0.02%	m

TOTAL	16,642.00	26.27%	14,044.00	23.16%	14,596.00	23.78%	15,638.00	23.44%	m

OTHER
NAV Basic	-		-		-		-
NAV Diluted	-		-		-		-

Astrazeneca Cash Flow Statement

%1$s Cash Flow Statement
	31 Dec 2017 (USD)	31 Dec 2018 (USD)	31 Dec 2019 (USD)	31 Dec 2020 (USD)
Operating CF	3,578.00	2,618.00	2,969.00	4,799.00	m
Pre-Financing CF	1,250.00	3,581.00	2,312.00	4,514.00	m
Retained CF	-1,686.00	1,537.00	547.00	2,311.00	m

Astrazeneca Brokers

%1$s Brokers
Name	Activity	Type	Mnemonic	Code
Evolution Securities Limited	Market Maker(MME)	Broker/Dealer	EVO	EVBGGB21MMT
Nyenburgh Holding B.V.	Market Maker(MME)	Broker/Dealer	NYBB	NYENNL2B
Winterflood Securities Ltd	Market Maker(MME)	Broker/Dealer	WINS	WNTSGB2LBIC